Pharma Business Pakistan

435 posts

The Great Divide in Pakistan Pharma Market – Suggestions for Smaller Companies – Asrar Qureshi’s Blog Post #1321

Asrar Qureshi’s Blog Post #1321 discusses strategies for smaller pharmaceutical companies in Pakistan to gain market traction amidst larger competitors. Key recommendations include focusing on specific therapeutic areas, establishing a flagship brand, differentiating offerings, enhancing doctor relationships, leveraging digital tools, forming partnerships, and optimizing resource allocation to build a credible market presence.
Share
View Post
  • 6 min

Pakistan Pharma Market – Uneven Distribution and Its Impact on Competition and Strategy – Asrar Qureshi’s Blog Post #1320

Pakistan’s pharmaceutical market is highly concentrated, with the top 50 companies holding nearly 90% of sales, leaving many smaller firms struggling. This disparity affects competition, innovation, and talent acquisition. Smaller firms often resort to survival strategies rather than growth, highlighting a need for stronger capabilities rather than just more companies.
Share
View Post
  • 6 min

The Exit of Multinational Pharmaceutical Companies from Pakistan – Part 3 – Asrar Qureshi’s Blog Post #1293

Asrar Qureshi’s blog discusses the exit of multinational pharmaceutical companies from Pakistan and the country’s potential to attract them back. Highlighting necessary reforms in pricing, regulation, and clinical research, it stresses a long-term vision for the pharmaceutical sector as vital for economic growth and public health security. Collaboration between domestic and multinational firms is essential for success.
Share
View Post
  • 6 min

The Exit of Multinational Pharmaceutical Companies from Pakistan – Part 2 – Asrar Qureshi’s Blog Post #1292

This blog post by Asrar Qureshi examines the exit of multinational pharmaceutical companies from Pakistan, analyzing its historical context and impacts on the healthcare system. While local firms maintain medicine availability, concerns arise regarding innovation and clinical research. The challenge remains to balance local manufacturing capabilities with the need for multinational investment and research.
Share
Scientist pipetting liquid into a tray in a laboratory setting with lab equipment and computer displaying graphs
View Post
  • 6 min

Why Multinational Pharmaceutical Companies Are Leaving Pakistan – Asrar Qureshi’s Blog Post #1291

Asrar Qureshi’s blog post discusses the exit of multinational pharmaceutical companies from the Pakistani market, highlighting historical contributions, major exits, and the challenges faced by these firms, such as drug price controls and currency depreciation. Despite local companies acquiring many brands, concerns about access to innovative therapies and a decline in research presence persist.
Share
View Post
  • 5 min

Cost of Incentives to Work Life Balance – Asrar Qureshi’s Blog Post #1258

Asrar Qureshi’s Blog Post 1257 discusses the impact of performance incentives in the pharmaceutical industry. While rewards drive productivity, they can also lead to work-life imbalance, burnout, and a narrow definition of success, emphasizing metrics over well-being. The post advocates for redesigning incentives to promote sustainable practices and prioritize employee wellness.
Share
View Post
  • 6 min

Doctors & Pharma Industry – Part 2 of 2 – Asrar Qureshi’s Blog Post #1218

Asrar Qureshi’s Blog Post #1218 addresses the complex relationship between pharmaceutical companies and doctors, emphasizing the need for ethical conduct in Pakistan’s healthcare system. It outlines a Code of Conduct for both sectors, aiming to balance industry collaboration with patient welfare, maintaining professionalism while avoiding conflicts of interest.
Share
View Post
  • 5 min

Doctors & Pharma Industry – Part 1 of 2 – Asrar Qureshi’s Blog Post 1217

The blog post by Asrar Qureshi explores the complex relationship between pharmaceutical companies and doctors, emphasizing its dual nature of necessity and ethical risk. It advocates for transparency and independence in education, particularly in the context of Pakistan’s healthcare challenges. The post highlights both issues and contributions of this relationship in improving patient access to treatment.
Share
View Post
  • 6 min

Pharmaceutical Distribution Systems – A Strategic Opportunity – Asrar Qureshi’s Blog Post #1215

Asrar Qureshi’s blog post discusses the urgent need for modernizing pharmaceutical distribution in Pakistan, shifting from a traditional logistics model to a strategic healthcare framework. It emphasizes cold-chain capabilities and digital transformation to improve patient outcomes as the market evolves towards specialty medicines and biologics, urging collaboration among stakeholders.
Share
View Post
  • 5 min

Novartis Pharma Exits from Pakistan – Asrar Qureshi’s Blog Post 1183

Asrar Qureshi’s Blog Post 1183 discusses Novartis Pakistan’s transfer to International Investment II Limited (IIL), emphasizing its implications for the pharmaceutical sector. While the change aims to ensure supply continuity and local management agility, there are concerns about potential risks, including access to innovative medicines and workforce stability. The deal represents a significant shift in Pakistan’s pharmaceutical landscape.
Share